Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

99.02USD
24 Feb 2020
Change (% chg)

$-4.12 (-3.99%)
Prev Close
$103.14
Open
$100.77
Day's High
$101.97
Day's Low
$97.75
Volume
1,200,339
Avg. Vol
677,732
52-wk High
$141.81
52-wk Low
$94.60

Latest Key Developments (Source: Significant Developments)

Alexion Reports Q4 Earnings Per Share $4.00
Thursday, 30 Jan 2020 

Jan 30 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS.Q4 GAAP EARNINGS PER SHARE $4.00.Q4 NON-GAAP EARNINGS PER SHARE $2.71.Q4 REVENUE $1.384 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.31 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $2.60 -- REFINITIV IBES DATA.QTRLY SOLIRIS NET PRODUCT SALES WERE $1,013.1 MILLION, COMPARED TO $976.7 MILLION IN Q4 OF 2018.SEES 2020 TOTAL REVENUES $5.5 BILLION TO $5.56 BILLION.FY2020 REVENUE VIEW $5.64 BILLION -- REFINITIV IBES DATA.SEES 2020 NON-GAAP EARNINGS PER SHARE $10.65 TO $10.85.FY2020 EARNINGS PER SHARE VIEW $11.37 -- REFINITIV IBES DATA.SEES 2020 GAAP EARNINGS PER SHARE $7.91 TO $8.71.UPDATED 2020 GUIDANCE INCLUDES FINANCIAL IMPACT OF RECENTLY ANNOUNCED AGREEMENT TO ACQUIRE ACHILLION.SEES 2020 SOLIRIS/ULTOMIRIS REVENUES $4,755 MILLION TO $4,800 MILLION.ALEXION PHARMACEUTICALS - QTRLY SOLIRIS NET PRODUCT SALES WERE $1,013.1 MILLION, COMPARED TO $976.7 MILLION.  Full Article

Achillion Shareholders Approve Agreement To Be Acquired By Alexion
Thursday, 19 Dec 2019 

Dec 19 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION SHAREHOLDERS APPROVE AGREEMENT TO BE ACQUIRED BY ALEXION.ACHILLION PHARMACEUTICALS INC - CONTINUES TO EXPECT TRANSACTION WITH ALEXION TO CLOSE IN FIRST HALF OF 2020.  Full Article

Alexion Pharmaceuticals Q3 Non-GAAP Earnings Per Share $2.79
Wednesday, 23 Oct 2019 

Oct 23 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS THIRD QUARTER 2019 RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $2.79.Q3 GAAP EARNINGS PER SHARE $2.08.Q3 REVENUE $1.263 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.24 BILLION.Q3 EARNINGS PER SHARE ESTIMATE $2.47 -- REFINITIV IBES DATA.ALEXION PHARMACEUTICALS - NEGATIVE IMPACT OF FOREIGN CURRENCY ON QTRLY TOTAL REVENUE YEAR-OVER-YEAR WAS LESS THAN 1%, OR $2.5 MILLION.INCREASING 2019 REVENUES AND EPS GUIDANCE.SEES 2019 TOTAL REVENUES $4,860 MILLION TO $4,890 MILLION.SEES 2019 GAAP EARNINGS PER SHARE $8.58 TO $8.78.SEES 2019 NON-GAAP EARNINGS PER SHARE $10.25 TO $10.40.ALEXION PHARMACEUTICALS - UPDATED 2019 GUIDANCE ASSUMES GAAP EFFECTIVE TAX RATE OF 5% TO 6% & NON-GAAP EFFECTIVE TAX RATE OF 13% TO 14% FOR YEAR.UPDATED GUIDANCE EXCLUDES FINANCIAL IMPACT OF AGREEMENT TO ACQUIRE ACHILLION.FY2019 EARNINGS PER SHARE VIEW $9.94, REVENUE VIEW $4.85 BILLION -- REFINITIV IBES DATA.  Full Article

Alexion Receives FDA Approval For Ultomiris For Atypical Hemolytic Uremic Syndrome
Saturday, 19 Oct 2019 

Oct 18 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION RECEIVES FDA APPROVAL FOR ULTOMIRIS® (RAVULIZUMAB-CWVZ) FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS- REGULATORY FILINGS FOR MARKETING AUTHORIZATIONS OF ULTOMIRIS FOR TREATMENT OF AHUS IN EU, JAPAN UNDER REVIEW WITH REGULATORS.  Full Article

Alexion Pharmaceuticals Says If Merger With Achillion Terminated Under Certain Circumstances, Achillion May Be Required To Pay Co Fee Equal To $20 Million
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION PHARMACEUTICALS - IF MERGER WITH ACHILLION TERMINATED UNDER CERTAIN CIRCUMSTANCES, ACHILLION MAY BE REQUIRED TO PAY CO FEE EQUAL TO $20 MILLION.ALEXION - TO PAY ACHILLION TERMINATION FEE EQUAL TO $30 MILLION, $40 MILLION, $50 MILLION OR $60 MILLION DEPENDING ON EXTENSION OF MERGER END DATE, TERMINATION DATE.  Full Article

Alexion To Acquire Achillion
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Achillion Pharmaceuticals Inc ::ALEXION TO ACQUIRE ACHILLION.ACHILLION PHARMACEUTICALS INC - INITIAL ALL-CASH TRANSACTION FOR $6.30 PER SHARE.ACHILLION PHARMACEUTICALS INC - DEAL FOR $6.30 PER SHARE.ACHILLION PHARMACEUTICALS INC - TOTAL TRANSACTION OF UP TO $8.30 PER SHARE WITH POTENTIAL ADDITIONAL CONTINGENT CONSIDERATIONS.ACHILLION PHARMACEUTICALS INC - INITIAL DEAL CONSIDERATION OF APPROXIMATELY $930 MILLION.ACHILLION PHARMACEUTICALS INC - ALEXION WILL ALSO BE ACQUIRING CASH CURRENTLY ON ACHILLION'S BALANCE SHEET.ACHILLION PHARMACEUTICALS - DEAL INCLUDES POTENTIAL FOR ADDITIONAL CONSIDERATION IN FORM OF NON-TRADEABLE CONTINGENT VALUE RIGHTS.ACHILLION PHARMA - AS OF SEPT. 30, 2019, CASH CURRENTLY ON ACHILLION'S BALANCE SHEET WAS ABOUT $230 MILLION.ACHILLION PHARMA - CVRS WILL BE PAID TO ACHILLION SHAREHOLDERS IF SOME CLINICAL & REGULATORY MILESTONES ARE ACHIEVED WITHIN SPECIFIED PERIODS.  Full Article

Alexion And Bridgebio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis Investigational Medicine
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND BRIDGEBIO ANNOUNCE JAPANESE LICENSE AGREEMENT FOR EIDOS’ TRANSTHYRETIN AMYLOIDOSIS (ATTR) INVESTIGATIONAL MEDICINE.ALEXION PHARMACEUTICALS INC - EIDOS GRANTS ALEXION EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE AG10 IN JAPAN.ALEXION PHARMACEUTICALS - EIDOS TO RECEIVE UPFRONT PAYMENT OF $25 MILLION AND EQUITY INVESTMENT OF $25 MILLION.ALEXION PHARMACEUTICALS INC - PHASE 3 STUDY OF AG10 IN ATTR CARDIOMYOPATHY UNDERWAY IN U.S. & EUROPE.ALEXION PHARMACEUTICALS INC - PHASE 3 TRIAL IN ATTR POLYNEUROPATHY PLANNED TO INITIATE IN SECOND HALF OF 2019.  Full Article

Alexion Pharmaceuticals Says European Patent Office To Not Grant Co Patent Application Relating To Pharmaceutical Composition Of Soliris
Friday, 6 Sep 2019 

Sept 5 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION PHARMACEUTICALS - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF SOLIRIS (ECULIZUMAB).ALEXION PHARMACEUTICALS INC - WILL EVALUATE OPTION TO APPEAL THE EUROPEAN PATENT OFFICE’S DECISION.ALEXION PHARMA - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF MATTER OF SOLIRIS (ECULIZUMAB).  Full Article

Alexion Pharmaceuticals Receives Marketing Authorization From EC For Ultomiris For Adults With PNH
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Alexion Pharmaceuticals Inc ::ULTOMIRIS® (RAVULIZUMAB) RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS - EC APPROVAL BASED ON RESULTS FROM TWO PHASE 3 STUDIES.  Full Article

FDA Grants Approval Of Soliris, A Treatment For Neuromyelitis Optica Spectrum Disorder, To Alexion Pharmaceuticals
Thursday, 27 Jun 2019 

June 27 (Reuters) - FDA::FDA APPROVES FIRST TREATMENT FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER, A RARE AUTOIMMUNE DISEASE OF THE CENTRAL NERVOUS SYSTEM.FDA SAYS GRANTED APPROVAL OF SOLIRIS TO ALEXION PHARMACEUTICALS.FDA SAYS SOLIRIS HAS A BOXED WARNING THAT LIFE-THREATENING AND FATAL MENINGOCOCCAL INFECTIONS HAVE OCCURRED IN PATIENTS TREATED WITH SOLIRIS.  Full Article

Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

Jan 7 Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than Alexion Pharmaceuticals Inc's Soliris, in a late-stage study.